CLAIMS

1. An IgG2 constant region in which His at position 147 (position 268 in the EU numbering system), Arg at position 234 (position 355 in the EU numbering system), and/or Gln at position 298 (position 419 in the EU numbering system) in the amino acid sequence of SEQ ID NO: 2 have been substituted with ~~other amino acids~~ Gln, Gln and Glu, respectively.

2. An IgG2 constant region in which Cys at position 14 (position 131 in the EU numbering system), Arg at position 16 (position 133 in the EU numbering system), Cys at position 102 (position 219 in the EU numbering system), Glu at position 20 (position 137 in the EU numbering system), Ser at position 21 (position 138 in the EU numbering system), His at position 147 (position 268 in the EU numbering system), Arg at position 234 (position 355 in the EU numbering system), and Gln at position 298 (position 419 in the EU numbering system) in the amino acid sequence of SEQ ID NO: 2 have been substituted with ~~other amino acids~~ Ser, Lys, Ser, Gly, Gly, Gln, Gln and Glu, respectively.

3. An IgG2 constant region in which Cys at position 14 (position 131 in the EU numbering system), Arg at position 16 (position 133 in the EU numbering system), Cys at position 102 (position 219 in the EU numbering system), Glu at position 20 (position 137 in the EU numbering system), Ser at position 21 (position 138 in the EU numbering system), His at position 147 (position 268 in the EU numbering system), Arg at position 234 (position 355 in the EU numbering system), Gln at position 298 (position 419 in the EU numbering system), and Asn at position 313 (position 434 in the EU numbering system) in the amino acid sequence of SEQ ID NO: 2 have been substituted with ~~other amino acids~~ Ser, Lys, Ser, Gly, Gly, Gln, Gln, Glu and Ala, respectively.

4. A human antibody constant region comprising the amino acid sequence of SEQ ID NO: 36.

5. An antibody comprising the constant region of any one of claims 1 to 4.

6. An anti-IL-6 receptor antibody comprising the constant region of any one of claims 1 to 4.

7. A pharmaceutical composition comprising the constant region of any one of claims 5 and 6.